Program
XMAB412
A development code. Also written as “XmAb412 Monoclonal Bispecific Antibody”.
Its studies are mostly in Inflammatory Bowel Diseases, led by Xencor.
Furthest: phase 1, since Jul 14, 20261 company-led study, 1 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xencor | 11 open or running | phase 1since Jul 14, 2026 | Jul 14, 2026 | Aug 2027phase 1 · NCT07713485 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2026First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT07713485 · 128 planned · Australia
- Nov 12, 2026Primary completion moved from 2027-05 to 2027-08Date moved laterphase 1 · +3 months · NCT07713485
Ahead
- Aug 2027Primary completion: phase 1 study in Inflammatory Bowel DiseasesNCT07713485
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07713485Inflammatory Bowel Diseases · Australia | 1 | Recruiting | Aug 2027 | 128 |
How it is read
Names in the registry
- “XmAb412 Monoclonal Bispecific Antibody”, 1 entry
Codes read as this program: XMAB412.
Conditions, from the studies’ own filings
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.